Abstract: Polyethylene glycol modifications of thymosin alpha 1 (T&agr; 1-PEGs), their preparation process, the medicine composition containing them, and their application in the medicine for preventing and treating diseases related with immune deficiency and hypoimmunity, including hepatitis B, hepatitis C, hepatoma, malignant melanoma, non-small cell lung cancer, SARS, and AIDS etc.
Type:
Grant
Filed:
November 11, 2006
Date of Patent:
December 20, 2011
Assignee:
Institute of Pharmacology and Toxicology Academy of Military Mecical Sciences, P.L.A., China